Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells

Allergic diseases are inflammatory disorders that involve many types of cells and factors, including allergens, immunoglobulin (Ig)E, mast cells, basophils, cytokines and soluble mediators. Among them, IgE plays a vital role in the development of acute allergic reactions and chronic inflammatory all...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jiayun, Chen, Jiajie, Ye, Lanlan, Cai, Zelang, Sun, Jinlu, Ji, Kunmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050685/
https://www.ncbi.nlm.nih.gov/pubmed/30026908
http://dx.doi.org/10.1186/s13601-018-0213-z
_version_ 1783340389128732672
author Hu, Jiayun
Chen, Jiajie
Ye, Lanlan
Cai, Zelang
Sun, Jinlu
Ji, Kunmei
author_facet Hu, Jiayun
Chen, Jiajie
Ye, Lanlan
Cai, Zelang
Sun, Jinlu
Ji, Kunmei
author_sort Hu, Jiayun
collection PubMed
description Allergic diseases are inflammatory disorders that involve many types of cells and factors, including allergens, immunoglobulin (Ig)E, mast cells, basophils, cytokines and soluble mediators. Among them, IgE plays a vital role in the development of acute allergic reactions and chronic inflammatory allergic diseases, making its control particularly important in the treatment of IgE-mediated allergic diseases. This review provides an overview of the current state of IgE targeted therapy development, focusing on three areas of translational research: IgE neutralization in blood; IgE-effector cell elimination; and IgE(+) B cell reduction. IgE-targeted medicines such as FDA approved drug Xolair (Omalizumab) represent a promising avenue for treating IgE-mediated allergic diseases given the pernicious role of IgE in disease progression. Additionally, targeted therapy for IgE-mediated allergic diseases may be advanced through cellular treatments, including the modification of effector cells.
format Online
Article
Text
id pubmed-6050685
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60506852018-07-19 Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells Hu, Jiayun Chen, Jiajie Ye, Lanlan Cai, Zelang Sun, Jinlu Ji, Kunmei Clin Transl Allergy Review Allergic diseases are inflammatory disorders that involve many types of cells and factors, including allergens, immunoglobulin (Ig)E, mast cells, basophils, cytokines and soluble mediators. Among them, IgE plays a vital role in the development of acute allergic reactions and chronic inflammatory allergic diseases, making its control particularly important in the treatment of IgE-mediated allergic diseases. This review provides an overview of the current state of IgE targeted therapy development, focusing on three areas of translational research: IgE neutralization in blood; IgE-effector cell elimination; and IgE(+) B cell reduction. IgE-targeted medicines such as FDA approved drug Xolair (Omalizumab) represent a promising avenue for treating IgE-mediated allergic diseases given the pernicious role of IgE in disease progression. Additionally, targeted therapy for IgE-mediated allergic diseases may be advanced through cellular treatments, including the modification of effector cells. BioMed Central 2018-07-18 /pmc/articles/PMC6050685/ /pubmed/30026908 http://dx.doi.org/10.1186/s13601-018-0213-z Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Hu, Jiayun
Chen, Jiajie
Ye, Lanlan
Cai, Zelang
Sun, Jinlu
Ji, Kunmei
Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells
title Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells
title_full Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells
title_fullStr Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells
title_full_unstemmed Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells
title_short Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells
title_sort anti-ige therapy for ige-mediated allergic diseases: from neutralizing ige antibodies to eliminating ige(+) b cells
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050685/
https://www.ncbi.nlm.nih.gov/pubmed/30026908
http://dx.doi.org/10.1186/s13601-018-0213-z
work_keys_str_mv AT hujiayun antiigetherapyforigemediatedallergicdiseasesfromneutralizingigeantibodiestoeliminatingigebcells
AT chenjiajie antiigetherapyforigemediatedallergicdiseasesfromneutralizingigeantibodiestoeliminatingigebcells
AT yelanlan antiigetherapyforigemediatedallergicdiseasesfromneutralizingigeantibodiestoeliminatingigebcells
AT caizelang antiigetherapyforigemediatedallergicdiseasesfromneutralizingigeantibodiestoeliminatingigebcells
AT sunjinlu antiigetherapyforigemediatedallergicdiseasesfromneutralizingigeantibodiestoeliminatingigebcells
AT jikunmei antiigetherapyforigemediatedallergicdiseasesfromneutralizingigeantibodiestoeliminatingigebcells

Ejemplares similares